Blue Owl Capital Holdings LP Lowers Position in Aquestive Therapeutics, Inc. $AQST

Blue Owl Capital Holdings LP lessened its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 58.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 525,000 shares of the company’s stock after selling 725,000 shares during the period. Aquestive Therapeutics accounts for approximately 0.3% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 29th largest holding. Blue Owl Capital Holdings LP’s holdings in Aquestive Therapeutics were worth $3,392,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares in the last quarter. Modern Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the second quarter worth $33,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth $60,000. Finally, Lineweaver Wealth Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the fourth quarter worth $65,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 15,741 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $65,639.97. Following the sale, the insider owned 241,117 shares in the company, valued at $1,005,457.89. This trade represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Barber sold 8,257 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the sale, the chief executive officer owned 660,574 shares in the company, valued at $2,833,862.46. The trade was a 1.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 403,947 shares of company stock valued at $1,685,450. 6.81% of the stock is currently owned by company insiders.

Analyst Ratings Changes

AQST has been the topic of a number of recent analyst reports. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $4.12 on Monday. The stock’s 50-day simple moving average is $4.15 and its two-hundred day simple moving average is $4.67. Aquestive Therapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $7.55. The company has a market capitalization of $516.85 million, a price-to-earnings ratio of -6.75 and a beta of 1.50.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million for the quarter, compared to analysts’ expectations of $10.90 million. On average, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.